Needham raised the firm’s price target on Alnylam (ALNY) to $377 from $320 and keeps a Buy rating on the shares after hosting an investor tour with its management team. The company has reiterated its 2025 total product revenue of $2.05B-2.25B, and the firm has come away incrementally more positive on the name and more bullish on the Amvuttra launch in ATTR-CM, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Promising Outlook: Analyst Joseph Stringer Raises Price Target Amid Optimism for Amvuttra Launch
- Alnylam’s NeuroFeeL Study: A New Frontier in Biomarker Research
- Alnylam price target raised to $360 from $300 at BMO Capital
- Alnylam Pharma Appoints New Chief R&D Officer
- Alnylam names Pushkal Garg as EVP, chief research and development officer